The London Stock Exchange uses cookies to improve its website. The cookies for analytical purposes have already been set. For more details and how to manage cookies, please see our privacy and cookies policy.

Description of business:
Biofrontera is a biopharmaceutical company operating out of Germany specialising in the development of medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Biofrontera's main product is Ameluz, a prescription drug approved for use in Europe for the treatment of Actinic Keratosis with photodynamic therapy. The Company is looking to further develop Ameluz for use with other medical conditions and obtain approval for use in other countries, in particular the USA.

Back

Biofrontera AG

Related links

Further informations about 7 and 7/30 days issues can be find by clicking on one of the options below:

Issues last 7 days

Last issues 7/30 days

Back to New and recent issues - Home



The Exchange accepts no responsibility for the content of the website you are now accessing or for any reliance placed by you or any person on the information contained on it.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.

You will be redirected in five seconds.

You are accessing the London Stock Exchange Annual Report Service powered by PrecisionIR.

The Exchange accepts no responsibility for the content of the reports you are now accessing or for any reliance placed by you or any person on the information contained therein.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.

You will be redirected in five seconds